Search

Your search keyword '"Navarro Ruiz, Andres"' showing total 24 results
Start Over Author "Navarro Ruiz, Andres"
24 results on '"Navarro Ruiz, Andres"'

13. Successful treatment of severe gastrointestinal bleeding secondary to Crohn disease with recombinant factor VIIa

Author

Girona, Eva, Borras-Blasco, Joaquin, Conesa-Garcia, Venancio, Navarro-Ruiz, Andres, Solis, Javier, Garcia-Sepulcre, Mariana Fe, and Oliver-Garcia, Israel

Subjects
Care and treatment, Dosage and administration, Health aspects, Gastrointestinal hemorrhage -- Care and treatment -- Health aspects, Crohn's disease -- Care and treatment -- Health aspects, Metronidazole -- Dosage and administration -- Health aspects, Omeprazole -- Dosage and administration -- Health aspects, Methylprednisolone -- Dosage and administration -- Health aspects
Abstract

A 58-year-old man diagnosed with ileocolonic Crohn disease was admitted to the emergency room with massive lower gastrointestinal hemorrhage and hypovolemic shock. Treatment was started with methylprednisolone, metronidazole and omeprazole. [...]

Published
2007

15. Unrecognized delayed toxic lithium peak concentration in an acute poisoning with sustained release lithium product

Author

Borras-Blasco, Joaquin, Sirvent, Ana Esther, Navarro-Ruiz, Andres, Murcia-Lopez, Ana, Romero-Crespo, Isabel, and Enriquez, Ricardo

Subjects
Diagnosis, Care and treatment, Health aspects, Lithium carbonate -- Health aspects, Heavy metal poisoning -- Diagnosis -- Care and treatment, Heavy metals -- Health aspects
Abstract

A 32-year-old female with a history of bipolar disorder was admitted after taking approximately 16 g of an extended-release lithium carbonate formulation in an attempted suicide. Five hours after consumption, [...]

Published
2007

18. Adverse cutaneous reactions induced by TNF-(alpha) antagonist therapy

Author

Borras-Blasco, Joaquin, Navarro-Ruiz, Andres, Borras, Consuelo, and Castera, Elvira

Subjects
Etanercept -- Complications and side effects, Etanercept -- Research, Infliximab -- Complications and side effects, Infliximab -- Research, Tumor necrosis factor -- Physiological aspects, Tumor necrosis factor -- Research, Drugs -- Adverse and side effects, Drugs -- Reports, Health
Published
2009

19. [Artículo traducido] Adherencia al tratamiento con quimioterapia oral en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico: protocolo para un estudio de vida real realizado en farmacia hospitalaria

Author

Mangues-Bafalluy, Irene, Bernárdez, Beatriz, Martínez-Sesmero, José Manuel, Navarro-Ruiz, Andres, Rubio-Salvador, Ana Rosa, and Martín-Conde, Maria Teresa

Abstract

este artículo describe un protocolo de estudio para evaluar la adherencia a la quimioterapia oral (QTO) en pacientes con cáncer de pulmón no microcítico (CPNM) localmente avanzado o metastásico en España.

Published
2024
Full Text
View/download PDF

23. A rapid validated UV-HPLC method for the simultaneous determination of the antiretroviral compounds darunavir and raltegravir in their dosage form

Author

Estan-Cerezo, Gabriel, Garcia-Monsalve, Ana, Soriano-Irigaray, Leticia, Francisco José Rodríguez-Lucena, and Navarro-Ruiz, Andres

Subjects
Dosage Forms, HAART, Anti-HIV Agents, Reproducibility of Results, Reference Standards, Sensitivity and Specificity, Drug Combinations, validation study, Limit of Detection, Raltegravir Potassium, Calibration, Spectrophotometry, Ultraviolet, HPLC, raltegravir, Chromatography, High Pressure Liquid, Darunavir
Abstract

Introduction. A rapid, simple and sensitive high-performance liquid chromatography (HPLC) method with ultraviolet detection has been developed for quantification of darunavir and raltegravir in their pharmaceutical dosage form. Material and methods. The assay enables the measurement of both drugs with a linear calibration curve (R-2 = 0.999) over the concentration range 5-100 mg/L. The determination was performed on an analytical Tracer Excel 120 ODSB (15x0.4.6 cm) column at 35 degrees C. The selected wavelength was 254 nm. The mobile phase was a mixture of 0.037 M sodium dihydrogen phosphate buffer, acetonitrile and methanol (40:50:10, v/v/v) at a flow rate of 2.0 mL/min Nevirapine (50 mg/L) was used as internal standard. Results. Accuracy, intra-day repeatability (n = 5), and inter-day precision (n = 3) were found to be satisfactory, being the accuracy from -4.33 to 3.88% and precisions were intra-day and inter-day, 0.25% and 4.42% respectively in case of darunavir. Raltegravir intra-day and inter-day precisions lower of 1.01 and 2.36%, respectively and accuracy values bet from -4.02 to 1.06%. Conclusions. Determination of the darunavir and raltegravir in their dosage form was done with a maximum deviation of 4%. This analytical method is rapid, easily implantable and offers good results.

Catalog

Books, media, physical & digital resources
See catalog results